- Home
- VRAX vs XBIO Comparison
VRAX vs XBIO Comparison
Compare VRAX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | XBIO |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 7.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRAX | XBIO |
|---|---|---|
| Price | $0.22 | $2.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 154.9K | 24.1K |
| Earning Date | 03-10-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.90 |
| 52 Week High | $1.34 | $13.93 |
Technical Indicators
Market Signals| Indicator | VRAX | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 51.41 |
| Support Level | $0.20 | $2.70 |
| Resistance Level | $0.25 | $3.12 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 47.77 | 27.04 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.